Core Insights - Nektar Therapeutics' stock surged 51% following positive Phase II trial results for its lead asset, rezpeg, in treating atopic dermatitis (AD) [1][6] Group 1: Trial Results - In the REZOLVE-AD study, a 24 µg/kg dose of rezpeg maintained disease control across four measures of AD severity at the one-year mark [2] - Among patients on a monthly dosing regimen who achieved EASI-50 during the 16-week induction, 71% and 80% achieved EASI-75 and EASI-90, respectively, after one year [3] - For quarterly-dosed patients meeting the same induction criteria, 83% and 78% achieved EASI-75 and EASI-90 at the one-year point [3] - Total AD clearance (EASI-100) was achieved by 22% of monthly dose patients and 18% of quarterly dose patients at week 52 [3] Group 2: Patient Outcomes - Rezpeg led to 85% and 63% of patients achieving vIGA-AD scores of 0 or 1 across monthly and quarterly dosing schedules at 52 weeks [4] - Improvement in itch NRS scores was observed in 75% of monthly and 77% of quarterly dosing patients [4] - During the maintenance period, 33% of previous non-responders in the monthly cohort achieved EASI-90, while 26% of the quarterly cohort experienced the same outcome [4] Group 3: Safety Profile - Rezpeg was found to be safe and tolerable, with the most common treatment-emergent adverse event being mild injection site reactions [5] - No serious adverse events such as conjunctivitis, oral ulcers, cardiovascular issues, or malignancies were reported [5] Group 4: Market Reaction - Following the Phase II results, Nektar's stock price increased from $37.07 to $56.00, reflecting investor confidence [6] - The stock may have also benefited from the announcement of a $3 million underwritten public offering of common stock [6] - Previous positive outcomes in the REZOLVE-AD study had already led to a significant stock increase of over 150% when data was presented at the EADV Congress in September 2025 [7]